$BMY Recent Headlines Alcoa shares rise on ear
Post# of 144503
Posted On: 01/16/2015 1:12:41 PM
$BMY Recent Headlines
Alcoa shares rise on earnings, sales beat 6:55 p.m. Jan. 12, 2015 - MarketWatch
Bristol-Myers Squibb shares rise 5.7% 9:30 a.m. Jan. 12, 2015 - Sue Chang
Engage sick bags as stormy markets show no signs of calm 8:58 a.m. Jan. 12, 2015 - Shawn Langlois
Bristol-Myers Squibb jumps on Opdivo cancer drug test 8:17 a.m. Jan. 12, 2015 - Angela Chen
Bristol-Myers' stock climbs 6.3% premarket after positive trial results for Opdivo 8:16 a.m. Jan. 12, 2015 - Tomi Kilgore
FDA approves Bristol-Myers’s skin cancer treatment Opdivo 6:09 p.m. Dec. 22, 2014 - Ron Winslow
Steelcase shares slide as revenue comes in light 5:42 p.m. Dec. 22, 2014 - MarketWatch
FDA approves Bristol-Myers Squibb's Opdivo drug for treatment of skin cancer 5:29 p.m. Dec. 22, 2014 - Tom Bemis
Drug makers face another $65 billion patent cliff 12:41 p.m. Dec. 10, 2014 - Russ Britt
4 stocks to watch 1:44 p.m. Nov. 19, 2014 - The Trading Deck
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Charting a bullish post-election backdrop 11:04 a.m. Nov. 5, 2014 - Michael Ashbaugh
6 stocks to watch 2:35 p.m. Oct. 29, 2014 - The Trading Deck
Updates, advisories and surprises 12:31 p.m. Oct. 24, 2014 - MarketWatch
Amazon, Pandora sink in wake of results; KLA-Tencor surges 10:48 a.m. Oct. 24, 2014 - Sue Chang
Bristol-Myers profit slips, but tops expectations 7:45 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers sees 2014 total sales $15.2 bln-$15.8 bln vs. FactSet consensus $15.58 bln 7:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers lowers 2014 net EPS outlook to $1.15-$1.25 from $1.50-$1.60 7:34 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers affirms 2014 adj. EPS outlook of $1.70-$1.80 7:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 FactSet sales consensus $3.81 bln 7:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers' Opdivo - The New Cash Cow 9:08 a.m. Today - Seeking Alpha
Veteran Analyst’s Top Health-Care Picks for 2015 11:38 a.m. Jan. 15, 2015 - Barrons.com
Eli Lilly Has 'Turned The Corner,' Upgraded 10:02 a.m. Jan. 15, 2015 - Investors Business Daily
Celldex Therapeutics Still Building Its Immuno-Oncology Story 5:40 p.m. Jan. 14, 2015 - Seeking Alpha
Express Scripts is Biotech's Grinch 9:13 a.m. Jan. 14, 2015 - Seeking Alpha
Bristol-Myers Squibb (BMY) Stock Rises Today After Eli Lilly Collaboration 11:42 a.m. Jan. 13, 2015 - TheStreet.com
Bristol’s Lung Cancer Drug Aces Trial, Cheers Bulls 10:58 a.m. Jan. 13, 2015 - Barrons.com
Lilly to Collaborate on Cancer Drug Trials 8:52 a.m. Jan. 13, 2015 - The Wall Street Journal Interactive Edition
Bristol-Myers and Lilly team up in cancer 8:32 a.m. Jan. 13, 2015 - Seeking Alpha
'Mad Money' Lightning Round: Hold Onto WhiteWave, Bristol-Myers 6:00 a.m. Jan. 13, 2015 - TheStreet.com
'Fast Money' Recap: More Monday Mayhem as Oil Falls, Volatility Runs Wild 5:00 a.m. Jan. 13, 2015 - TheStreet.com
Medical Marijuana Goes to Market in Canada 3:10 a.m. Jan. 13, 2015 - InvestorPlace.com
Cramer's Lightning Round - Zimmer's Sweet Spot In The Marketplace (1/12/15) 1:32 a.m. Jan. 13, 2015 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses 8:32 p.m. Jan. 12, 2015 - TheStreet.com
Celgene, Bristol-Myers Cancer Drug News Lifts Stocks 5:48 p.m. Jan. 12, 2015 - Investors Business Daily
U.S. Stocks End Lower 4:41 p.m. Jan. 12, 2015 - The Wall Street Journal Interactive Edition
Gilead CEO’s Latest Sale Totals $14.3M 1:47 p.m. Jan. 12, 2015 - Barrons.com
Seattle Genetics and Bristol-Myers team up in blood cancer trials 1:44 p.m. Jan. 12, 2015 - Seeking Alpha
Bristol-Myers Hits 14-Year High On Cancer Drug Trial 1:25 p.m. Jan. 12, 2015 - Investors Business Daily
Why Bristol-Myers, Lululemon, and Foundation Medicine Are 3 of Today’s Best Stocks 10:39 a.m. Jan. 12, 2015 - InvestorPlace.com
Global Ankylosing Spondylitis Market 2015-2019 4:16 p.m. Jan. 14, 2015 - PR Newswire - PRF
Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors 8:02 a.m. Jan. 13, 2015 - BusinessWire - BZX
Bucking the Trend: New Research on RadioShack, Lululemon, Tekmira, Bristol-Myers and Alcoa 7:50 a.m. Jan. 13, 2015 - PR Newswire - PRF
Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin)and Opdivo® (Nivolumab) in Hematologic Malignancies 8:01 a.m. Jan. 12, 2015 - BusinessWire - BZX
CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early 9:06 p.m. Jan. 11, 2015 - BusinessWire - BZX
Global Psoriasis Therapeutics Market 2015-2019 2:12 p.m. Jan. 7, 2015 - PR Newswire - PRF
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference 9:30 a.m. Jan. 6, 2015 - BusinessWire - BZX
Stocks Cheering This Festive Season: Featured Research on Bristol-Myers, Rite Aid, Boeing, TASER and BioCryst 9:10 a.m. Dec. 23, 2014 - PR Newswire - PRF
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration 5:21 p.m. Dec. 22, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab) 3:11 p.m. Dec. 22, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27 10:01 a.m. Dec. 17, 2014 - BusinessWire - BZX
Pharma Equities Technical Analysis -- GlaxoSmithKline, Bristol-Myers Squibb, Teva Pharmaceutical Industries, Endo Intl., and Allergan 9:05 a.m. Dec. 17, 2014 - PR Newswire - PRF
Fitch Revises Bristol-Myers Squibb's Outlook to Stable; Affirms IDR at 'A-' 3:00 p.m. Dec. 11, 2014 - BusinessWire - BZX
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors 6:00 a.m. Dec. 10, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Announces Dividend 4:30 p.m. Dec. 9, 2014 - BusinessWire - BZX
Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma 1:00 p.m. Dec. 6, 2014 - BusinessWire - BZX
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Millionin New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries 9:01 a.m. Dec. 1, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C 11:34 a.m. Nov. 26, 2014 - BusinessWire - BZX
Alcoa shares rise on earnings, sales beat 6:55 p.m. Jan. 12, 2015 - MarketWatch
Bristol-Myers Squibb shares rise 5.7% 9:30 a.m. Jan. 12, 2015 - Sue Chang
Engage sick bags as stormy markets show no signs of calm 8:58 a.m. Jan. 12, 2015 - Shawn Langlois
Bristol-Myers Squibb jumps on Opdivo cancer drug test 8:17 a.m. Jan. 12, 2015 - Angela Chen
Bristol-Myers' stock climbs 6.3% premarket after positive trial results for Opdivo 8:16 a.m. Jan. 12, 2015 - Tomi Kilgore
FDA approves Bristol-Myers’s skin cancer treatment Opdivo 6:09 p.m. Dec. 22, 2014 - Ron Winslow
Steelcase shares slide as revenue comes in light 5:42 p.m. Dec. 22, 2014 - MarketWatch
FDA approves Bristol-Myers Squibb's Opdivo drug for treatment of skin cancer 5:29 p.m. Dec. 22, 2014 - Tom Bemis
Drug makers face another $65 billion patent cliff 12:41 p.m. Dec. 10, 2014 - Russ Britt
4 stocks to watch 1:44 p.m. Nov. 19, 2014 - The Trading Deck
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Charting a bullish post-election backdrop 11:04 a.m. Nov. 5, 2014 - Michael Ashbaugh
6 stocks to watch 2:35 p.m. Oct. 29, 2014 - The Trading Deck
Updates, advisories and surprises 12:31 p.m. Oct. 24, 2014 - MarketWatch
Amazon, Pandora sink in wake of results; KLA-Tencor surges 10:48 a.m. Oct. 24, 2014 - Sue Chang
Bristol-Myers profit slips, but tops expectations 7:45 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers sees 2014 total sales $15.2 bln-$15.8 bln vs. FactSet consensus $15.58 bln 7:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers lowers 2014 net EPS outlook to $1.15-$1.25 from $1.50-$1.60 7:34 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers affirms 2014 adj. EPS outlook of $1.70-$1.80 7:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 FactSet sales consensus $3.81 bln 7:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers' Opdivo - The New Cash Cow 9:08 a.m. Today - Seeking Alpha
Veteran Analyst’s Top Health-Care Picks for 2015 11:38 a.m. Jan. 15, 2015 - Barrons.com
Eli Lilly Has 'Turned The Corner,' Upgraded 10:02 a.m. Jan. 15, 2015 - Investors Business Daily
Celldex Therapeutics Still Building Its Immuno-Oncology Story 5:40 p.m. Jan. 14, 2015 - Seeking Alpha
Express Scripts is Biotech's Grinch 9:13 a.m. Jan. 14, 2015 - Seeking Alpha
Bristol-Myers Squibb (BMY) Stock Rises Today After Eli Lilly Collaboration 11:42 a.m. Jan. 13, 2015 - TheStreet.com
Bristol’s Lung Cancer Drug Aces Trial, Cheers Bulls 10:58 a.m. Jan. 13, 2015 - Barrons.com
Lilly to Collaborate on Cancer Drug Trials 8:52 a.m. Jan. 13, 2015 - The Wall Street Journal Interactive Edition
Bristol-Myers and Lilly team up in cancer 8:32 a.m. Jan. 13, 2015 - Seeking Alpha
'Mad Money' Lightning Round: Hold Onto WhiteWave, Bristol-Myers 6:00 a.m. Jan. 13, 2015 - TheStreet.com
'Fast Money' Recap: More Monday Mayhem as Oil Falls, Volatility Runs Wild 5:00 a.m. Jan. 13, 2015 - TheStreet.com
Medical Marijuana Goes to Market in Canada 3:10 a.m. Jan. 13, 2015 - InvestorPlace.com
Cramer's Lightning Round - Zimmer's Sweet Spot In The Marketplace (1/12/15) 1:32 a.m. Jan. 13, 2015 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses 8:32 p.m. Jan. 12, 2015 - TheStreet.com
Celgene, Bristol-Myers Cancer Drug News Lifts Stocks 5:48 p.m. Jan. 12, 2015 - Investors Business Daily
U.S. Stocks End Lower 4:41 p.m. Jan. 12, 2015 - The Wall Street Journal Interactive Edition
Gilead CEO’s Latest Sale Totals $14.3M 1:47 p.m. Jan. 12, 2015 - Barrons.com
Seattle Genetics and Bristol-Myers team up in blood cancer trials 1:44 p.m. Jan. 12, 2015 - Seeking Alpha
Bristol-Myers Hits 14-Year High On Cancer Drug Trial 1:25 p.m. Jan. 12, 2015 - Investors Business Daily
Why Bristol-Myers, Lululemon, and Foundation Medicine Are 3 of Today’s Best Stocks 10:39 a.m. Jan. 12, 2015 - InvestorPlace.com
Global Ankylosing Spondylitis Market 2015-2019 4:16 p.m. Jan. 14, 2015 - PR Newswire - PRF
Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors 8:02 a.m. Jan. 13, 2015 - BusinessWire - BZX
Bucking the Trend: New Research on RadioShack, Lululemon, Tekmira, Bristol-Myers and Alcoa 7:50 a.m. Jan. 13, 2015 - PR Newswire - PRF
Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin)and Opdivo® (Nivolumab) in Hematologic Malignancies 8:01 a.m. Jan. 12, 2015 - BusinessWire - BZX
CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early 9:06 p.m. Jan. 11, 2015 - BusinessWire - BZX
Global Psoriasis Therapeutics Market 2015-2019 2:12 p.m. Jan. 7, 2015 - PR Newswire - PRF
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference 9:30 a.m. Jan. 6, 2015 - BusinessWire - BZX
Stocks Cheering This Festive Season: Featured Research on Bristol-Myers, Rite Aid, Boeing, TASER and BioCryst 9:10 a.m. Dec. 23, 2014 - PR Newswire - PRF
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration 5:21 p.m. Dec. 22, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab) 3:11 p.m. Dec. 22, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27 10:01 a.m. Dec. 17, 2014 - BusinessWire - BZX
Pharma Equities Technical Analysis -- GlaxoSmithKline, Bristol-Myers Squibb, Teva Pharmaceutical Industries, Endo Intl., and Allergan 9:05 a.m. Dec. 17, 2014 - PR Newswire - PRF
Fitch Revises Bristol-Myers Squibb's Outlook to Stable; Affirms IDR at 'A-' 3:00 p.m. Dec. 11, 2014 - BusinessWire - BZX
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors 6:00 a.m. Dec. 10, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Announces Dividend 4:30 p.m. Dec. 9, 2014 - BusinessWire - BZX
Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma 1:00 p.m. Dec. 6, 2014 - BusinessWire - BZX
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Millionin New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries 9:01 a.m. Dec. 1, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C 11:34 a.m. Nov. 26, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼